Navigation Links
Covance Elects Bradley T. Sheares to Company's Board of Directors
Date:2/19/2009

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Bradley T. Sheares, Ph. D., to its Board of Directors.

Dr. Sheares is former chief executive officer and member of the Board of Directors of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a portfolio of branded cardiovascular medicines. Prior to joining Reliant, he was president of the U.S. Human Health division of Merck and Co., Inc., where he led commercial efforts in the United States for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases. In addition to this role, Dr. Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, managing operations and setting corporate policies. He joined Merck in 1987 as research fellow in the Merck Research Laboratories, and he held positions of increasing responsibility in Merck until his departure in 2006.

"We are very pleased to welcome Dr. Sheares to our Board of Directors. His scientific background, academic achievements and extensive experience in bringing new medicines to the market will strengthen Covance's ability to provide innovative drug development solutions to our clients, " said Joe Herring, Covance chairman and CEO. "We look forward to leveraging Dr. Sheares' outstanding record of leadership and management, as well as his focus on recruiting top talent, to help our company sustain its leadership position in the industry and continue to provide value to our shareholders and employees."

"Covance has been at the forefront of creating innovative models of outsourcing," said Dr. Sheares. "I am thrilled at the opportunity to be part of such an accomplished group of individuals and to leverage my health care experience in enhancing the company's ability to deliver high-quality service and integrated solutions to its clients."

Dr. Sheares also serves on the Board of Directors of Honeywell International, a diversified technology and manufacturing company, and The Progressive Corporation, one of the nation's largest insurance holding companies. In addition, he serves on the Board of Trustees of Spelman College and is a member of the College of Physicians of Philadelphia, the Abington Friends School Committee, the Scientific Advisory Council for Montclair State University, and the Executive Leadership Council. He is the former chair of the Board of Directors of the National Pharmaceutical Council, which focuses on broadly communicating the economic, clinical and societal value of pharmaceuticals.

Dr. Sheares graduated summa cum laude with a bachelor's degree in chemistry from Fisk University and earned his doctorate in biochemistry from Purdue University. He completed his postdoctoral training as a Lucille P. Markey Scholar and NIH Research Fellow at the Massachusetts Institute of Technology.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 20 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the 2009 UBS Global Healthcare Services Conference
2. Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
3. Covance Reports Fourth Quarter and Full-Year 2008 Results
4. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2008 Financial Results Conference Call
6. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
7. Covance to Present at the Credit Suisse 2008 Healthcare Conference
8. Covance and Lilly Enter Into a Strategic R&D Collaboration
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... Plains, NJ (PRWEB) , ... January 19, 2017 ... ... board certified dermatologist by the American Board of Dermatology and fellowship trained Mohs ... of the National Institutes of Health, Dr. Li completed his internship in internal ...
(Date:1/19/2017)... Angeles, California (PRWEB) , ... January 19, 2017 ... ... the hands of a doctor who administered fillers that resulted in severe facial ... unprecedented case was taken on by doctors at UCLA Medical Center, who removed ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... financial planning assistance to commercial and residential clients in the California Bay Area, is ... positive heart health in the region. , Heart disease is the primary killer of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug delivery ... by 2021 from USD 1,179.20 billion in 2016, at ... Increasing prevalence of chronic diseases, increasing demand for biologics, ... driving the growth of this market. Whereas, self-administration & ... drugs offer significant growth opportunities for players operating in ...
Breaking Medicine Technology: